Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth
Update your Virtual Booth on PharmaCompass, ask us ![]()
About
Clinical OutsourcingClinical Outsourcing
Not Confirmed
Not Confirmed
03-04 March, 2026
Natural Product Expo W...Natural Product Expo West
Not Confirmed
Not Confirmed
03-06 March, 2026
Natural Products ExpoNatural Products Expo
Not Confirmed
Not Confirmed
03-06 March, 2026
List your booth number for exhibitions, ask us
CONTACT DETAILS




Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Events
Webinars & Exhibitions
Clinical OutsourcingClinical Outsourcing
Industry Trade Show
Not Confirmed
03-04 March, 2026
Natural Product Expo W...Natural Product Expo West
Industry Trade Show
Not Confirmed
03-06 March, 2026
Natural Products ExpoNatural Products Expo
Industry Trade Show
Not Confirmed
03-06 March, 2026
Digital content

26 Feb 2026
// BUSINESSWIRE
https://www.businesswire.com/news/home/20260226901519/en/Synthekine-Announces-Clinical-Trial-Collaboration-with-Merck-to-Evaluate-STK-012-In-Combination-with-Keytruda-Pembrolizumab-and-Chemotherapy-in-Ongoing-Randomized-Phase-2-Trial-in-First-Line-PD-L1-Negative-Nonsquamous-Non-Small-Cell-Lung-Cancer

23 Feb 2026
// PHARMIWEB
https://www.pharmiweb.com/press-release/2026-02-23/synthekine-appoints-biotechnology-and-pharmaceutical-industry-veteran-john-a-orwin-as-chair-of-its

13 Nov 2025
// BUSINESSWIRE
https://www.businesswire.com/news/home/20251113131381/en/First-Patient-Dosed-in-SYNERGY-101-a-Global-Randomized-Phase-2-Clinical-Trial-of-STK-012-in-First-Line-PD-L1-Negative-Nonsquamous-Non-Small-Cell-Lung-Cancer

07 Nov 2025
// BUSINESSWIRE
https://www.businesswire.com/news/home/20251107945337/en/Synthekine-Presents-Positive-Initial-Results-from-Phase-1a1b-Clinical-Trial-of-STK-012-Plus-Pembrolizumab-and-Chemotherapy-in-First-Line-PD-L1-Negative-Nonsquamous-Non-Small-Cell-Lung-Cancer

30 Oct 2025
// BUSINESSWIRE
https://www.businesswire.com/news/home/20251030999592/en/Synthekine-Announces-Late-Breaking-Oral-Presentation-of-Initial-Clinical-Data-of-STK-012-Plus-Pembrolizumab-and-Chemotherapy-in-First-Line-PD-L1-Negative-Nonsquamous-NSCLC-at-SITC-2025-Annual-Meeting

09 Dec 2024
// BUSINESSWIRE
ABOUT THIS PAGE